BTCRC-GYN15-013
Phase II Study of Pembrolizumab in Combination With Carboplatin and Paclitaxel for Advanced or Recurrent Endometrial Adenocarcinoma
BTCRC-HEM15-028
Phase I/II Study of Ixazomib and Romidepsin in Relapsed/ Refractory Peripheral T-cell Lymphoma (PTCL): Big Ten Cancer Research Consortium BTCRC-HEM15-028
BTCRC-HEM16-085
Phase II study of nivolumab and the antagonistic CSF-1R monoclonal antibody cabiralizumab (BMS-986227) in patients with relapsed/refractory peripheral T cell lymphoma
BTCRC-HEM17-092
Phase I/II study augmenting TAK-659 action in relapsed/refractory AML by addition of the proteasome inhibitor Ixazomib: Big Ten Cancer Research Consortium BTCRC-HEM17-092
BTCRC-LUN15-017
A Phase Ib/II Study of Anti-PD-1 Antibody Pembrolizumab and Imprime PGG for Patients with Metastatic Non-small Cell Lung Cancer After Progression on First-Line Chemotherapy
BTCRC-LUN15-029
A Phase II Trial of Chemotherapy plus Pembrolizumab in patients with advanced NSCLC previously treated with PD-1 or PD-L1 Inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029
BTCRC-LUN16-081
Phase II Study of Consolidation Immunotherapy with Nivolumab and Ipilimumab or Nivolumab alone following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
BTCRC-LUN17-139
A Phase II Study of Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer
BTCRC-LUN18-363
A Phase II Study of Chemo-Immunotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Big Ten Cancer Research Consortium BTCRC-LUN18-363
BTCRC-LUN17-127
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer: Big Ten Cancer Research Consortium. BTCRC-LUN17-127
BTCRC-LUN19-396
A Phase II Study of Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select IIIA [T3N1, T4N0-1] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)
BTCRC-LYM17-145
Phase Ib dose de-escalation study of the PI3K alpha/delta inhibitor, Copanlisib given in combination with the immunotherapeutic agents, Nivolumab and Rituximab in patients with relapsed/refractory indolent lymphoma. Big Ten Cancer Research Consortium BTCRC-LYM17-145
TBCRC044
A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease
LUN13-175
A Phase I/II Study of Carboplatin/Nab-Paclitaxel and MK-3475 for Advanced Non-Small Cell Lung Cancer (NSCLC): LUN13-175
LUN08-129
Phase II Study of Concurrent Pemetrexed and Radiation for Stage III Non-Small Cell Lung Cancer
LUN07-130
A Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies
HCRN-LUN06-116
Protocol H6Q-MC-S034(a) Randomized, Double-Blind, Phase 2 Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Chemonaive Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
LUN06-113
A Randomized Double Blind Phase II Trial of Cisplatin Plus Etoposide With/Without Concurrent ZD6474 in Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: Hoosier Oncology Group LUN06-113
LUN06-107
A Phase II Trial of Concurrent Cisplatin/ Etoposide/ Radiotherapy Followed by Consolidation Sorafenib in Patients with Inoperable Stage III Non-Small Cell Lung Cancer (NSCLC)
LUN05-99
Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer (SCLC): A Safety, Feasibility and Efficacy Study
LUN04-79
A Phase I-IIa Dose-Ranging Study of Pemetrexed (Alimta) Plus Cetuximab (Erbitux) in Patients With Recurrent Non-Small Cell Lung Cancer (NSCLC): Hoosier Oncology Group LUN04-79
LUN04-78
Pemetrexed (Alimta) in Patients with Chemosensitive and Chemoresistant Relapsed Small Cell Lung Cancer
LUN04-77
A Phase II Study of Erlotinib With Bevacizumab in Chemotherapy Naïve Performance Status (PS) 2 Patients With Advanced Non-Small Cell Lung Cancer
HCRN-LUN02-50
A Phase II Trial of Gefitinib (Iressa®) Plus Celecoxib (Celebrex®) in Chemotherapy-naïve Patients with Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC)
HCRN-LUN02-29
A Phase II Trial of ZD1839 (IRESSA®) in Both Patients with Chemosensitive and Chemorefractory Relapsed Neuroendocrine Cancers
HCRN-LUN01-25
Phase Ib/IIa Study of an Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination with Carboplatin-Paclitaxel in Patients with Chemo-therapy Naïve Advanced Non Small Cell Lung Cancer
LUN01-24
A Phase III Trial of Cisplatin/Etoposide/Radiotherapy With or Without Consolidation Docetaxel in Patients With Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC): Hoosier Oncology Group LUN01-24
HCRN-LUN01-15
A Phase III Randomized Study of Taxotere 75/mg/M2 vs. ALIMTA for Second-line Chemo for Non-Small Cell Lung Cancer
HCRN-LUN00-12
A Randomized, Phase III Trial Comparing CPT-11/ Cisplatin with Etoposide/Cisplatin in Patients with Previously Untreated, Extensive Small-Cell Lung Cancer
HCRN-LUN98-1
A Phase II Study of Weekly Paclitaxel Plus Gemcitabine in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
BRE09-146
PARP Inhibition After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer or ER/PR +, HER2 Negative With Known BRCA1/2 Mutations: Hoosier Oncology Group BRE09-146
BRE07-126
A Phase II Study of Lonafarnib in Patients with Locally advanced and Metastatic Breast Cancer: Hoosier Oncology Group: BRE07-126
HCRN-LUN97-1
A Phase II Study of Taxol + Carboplatin + Radiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer
BRE06-120
A Biological Sample Collection Protocol of Women With and Without Breast Cancer: Hoosier Oncology Group Study BRE06-120 for the Analytical Proteomics Team
HCRN-LUN96-2
A Phase II Study of Carboplatin plus Gemcitabine in Metastatic Non-Small Cell Lung Cancer
HCRN-LUN96-1
A Phase II Study of Paclitaxel (3-Hour Infusion and Bolus Doxorubicin in Recurrent or Refractory Small Cell Lung Cancer
BRE06-109
A Phase II Study of Combined VEGF Inhibitor (Bevacizumab + Sorafenib) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group Study BRE06-109
HCRN-LUN95-1
A Phase III Study of Gemcitabine +Cisplatin vs Cisplatin Alone in Patients with Metastatic Non-Small Cell Lung Cancer
HCRN-LUN93-4
A Phase II Study of Gemcitabine + Cisplatin in Non-Small Cell Lung Cancer
BRE05-97
A Phase II Study of Oral Enzastaurin in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane-Containing Regimen
HCRN-GU14-202
Combined Targeting of the Androgen Receptor in Metastatic Castrate-Resistant Prostate Cancer with Enzalutamide and the Poly (ADP-Ribose) Polymerase [PARP] Inhibitor Niraparib
BRE04-80
A Phase I/II Study of PTK787 in Combination with Trastuzumab in Patients with Newly Diagnosed HER-2 Overexpressing Locally Recurrent or Metastatic Breast Cancer
HCRN-LUN93-3
A Phase II Study of VP-16 plus Ifosfamide plus Cisplatin (VIP) plus Concurrent Radiation Therapy for Previously Untreated Limited Small Cell Lung Cancer
GU13-170
Androgen Deprivation Therapy With or Without Radium-223 Dichloride in Patients With Newly Diagnosed Metastatic Prostate Cancer With Bone Metastases: Hoosier Cancer Research Network GU13-170
BRE03-61
A Phase II Trial of Capecitabine, Oxaliplatin and Trastuzumab (CAPOX-T) in Patients with Previously Treated HER-2 Positive Metastatic Breast Cancer
GU12-159
The Pacific Clinical Trial: A Randomized Phase II Study Evaluating OGX-427 in Patients With Metastatic Castrate-Resistant Prostate Cancer (MCRPC)Who Have Prostate-Specific Antigen (PSA) Progression While Receiving Abiraterone: Hoosier Oncology Group GU12-159
BRE03-60
A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE03-60
GU12-160
The Borealis-2 Clinical Trial: A Randomized Phase 2 Study Comparing Docetaxel Alone to Docetaxel in Combination With OGX-427 in Patients With Relapsed or Refractory Metastatic Urothelial Carcinoma After Receiving a Platinum-containing Regimen: Hoosier Cancer Research Network GU12-160
QL12-153
Phase II Study of Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Patients With Germ Cell Tumors Undergoing 5 Day Cisplatin-based Chemotherapy: Hoosier Oncology Group Study QL12-153
HCRN-LUN93-2
A Phase III Trial of Maintenance Daily Oral VP-16 vs no Further Therapy Following Induction Chemotherapy with VP-16 plus Ifosfamide plus Cisplatin (VIP) in Extensive Small Cell Lung Cancer
